Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview

Higgins, 1992, ABC transporters: from microorganisms to man, Annu. Rev. Cell Biol., 8, 67, 10.1146/annurev.cb.08.110192.000435 Borst, 2000, A family of drug transporters: the multidrug resistance-associated proteins, J. Natl. Cancer Inst., 92, 1295, 10.1093/jnci/92.16.1295 Hipfner, 1999, Structural, mechanistic, and clinical aspects of MRP1, Biochim. Biophys. Acta, 1461, 359, 10.1016/S0005-2736(99)00168-6 König, 1999, Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance, Biochim. Biophys. Acta, 1461, 377, 10.1016/S0005-2736(99)00169-8 Senior, 1997, ATP hydrolysis cycles and mechanism in P-glycoprotein and CFTR, Semin. Cancer Biol., 8, 143, 10.1006/scbi.1997.0065 Ambudkar, 1999, Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annu. Rev. Pharmacol. Toxicol., 39, 361, 10.1146/annurev.pharmtox.39.1.361 Schinkel, 1997, The physiological function of drug-transporting P-glycoproteins, Semin. Cancer Biol., 8, 161, 10.1006/scbi.1997.0068 Schinkel, 1999, P-glycoprotein, a gatekeeper in the blood–brain barrier, Adv. Drug Deliv. Rev., 36, 179, 10.1016/S0169-409X(98)00085-4 Ayrton, 2001, Role of transport proteins in drug absorption, distribution and excretion, Xenobiotica, 31, 469, 10.1080/00498250110060969 Maliepaard, 2001, Subcellular localization and distribution of the breast cancer resistance protein in normal human tissues, Cancer Res., 61, 3458 van Veen, 2000, The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism, EMBO J., 19, 2503, 10.1093/emboj/19.11.2503 Chang, 2001, Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters, Science, 293, 1793, 10.1126/science.293.5536.1793 Özvegy, 2001, Functional characterization of the human multidrug transporter, abcg2, expressed in insect cells, Biochem. Biophys. Res. Commun., 285, 111, 10.1006/bbrc.2001.5130 Honjo, 2001, Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells, Cancer Res., 61, 6635 Kage, 2002, Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S–S homodimerization, Int. J. Cancer, 97, 626, 10.1002/ijc.10100 Schinkel, 1993, N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein, J. Biol. Chem., 268, 7474, 10.1016/S0021-9258(18)53199-9 Juliano, 1976, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochim. Biophys. Acta, 455, 152, 10.1016/0005-2736(76)90160-7 Huisman, 2000, Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors, AIDS, 14, 237, 10.1097/00002030-200002180-00005 Sikic, 1999, Modulation of multidrug resistance: a paradigm for translational clinical research, Oncology (Huntingt.), 13, 183 Litman, 2001, From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance, Cell. Mol. Life Sci., 58, 931, 10.1007/PL00000912 Higgins, 1992, Is the multidrug transporter a flippase?, Trends Biochem. Sci., 17, 18, 10.1016/0968-0004(92)90419-A Smit, 1993, Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease, Cell, 75, 451, 10.1016/0092-8674(93)90380-9 Smith, 1994, The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice, FEBS Lett., 354, 263, 10.1016/0014-5793(94)01135-4 van Helvoort, 1996, MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine, Cell, 87, 507, 10.1016/S0092-8674(00)81370-7 Tsuruo, 1981, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil, Cancer Res., 41, 1967 Boesch, 1991, In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833, Cancer Res., 51, 4226 Smith, 1998, Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum, J. Natl. Cancer Inst., 90, 1161, 10.1093/jnci/90.15.1161 Fischer, 1998, The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A, Drug Met. Disp., 26, 802 Hyafil, 1993, In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative, Cancer Res., 53, 4595 Malingré, 2001, Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients, Br. J. Cancer, 84, 42, 10.1054/bjoc.2000.1543 de Bruin, 1999, Reversal of drug resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR, Cancer Lett., 146, 117, 10.1016/S0304-3835(99)00182-2 Dantzig, 1996, Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979, Cancer Res., 56, 4171 Dantzig, 2001, Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic, Curr. Med. Chem., 8, 39, 10.2174/0929867013373903 Mistry, 2001, In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576, Cancer Res., 61, 749 Newman, 2000, Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance, Cancer Res., 60, 2964 Thiebaut, 1987, Cellular localization of the multidrug resistance gene product in normal human tissues, Proc. Natl. Acad. Sci. USA, 84, 7735, 10.1073/pnas.84.21.7735 Cordon-Cardo, 1989, Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites, Proc. Natl. Acad. Sci. USA, 86, 695, 10.1073/pnas.86.2.695 Schinkel, 1994, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs, Cell, 77, 491, 10.1016/0092-8674(94)90212-7 Schinkel, 1995, Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A, J. Clin. Invest., 96, 1698, 10.1172/JCI118214 Schinkel, 1996, P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs, J. Clin. Invest., 97, 2517, 10.1172/JCI118699 Choo, 2000, Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes, Drug Metab. Disp., 28, 655 Saito, 2001, Homozygous disruption of the mdr1a P-glycoprotein gene affects blood–nerve barrier function in mice administered with neurotoxic drugs, Acta Otolaryngol., 121, 735, 10.1080/00016480152583683 Lankas, 1998, Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice, Reprod. Toxicol., 12, 457, 10.1016/S0890-6238(98)00027-6 Sugawara, 1988, Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRP16, Cancer Res., 48, 1926 Smit, 1999, Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure, J. Clin. Invest., 104, 1441, 10.1172/JCI7963 Huisman, 2001, P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir, Mol. Pharmacol., 59, 806, 10.1124/mol.59.4.806 Mayer, 1996, Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein, Br. J. Pharmacol., 119, 1038, 10.1111/j.1476-5381.1996.tb15775.x Sparreboom, 1997, Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine, Proc. Natl. Acad. Sci. USA, 94, 2031, 10.1073/pnas.94.5.2031 Panwala, 1998, A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis, J. Immunol., 161, 5733, 10.4049/jimmunol.161.10.5733 Smit, 1998, Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted, Br. J. Pharmacol., 124, 416, 10.1038/sj.bjp.0701845 Schuetz, 2000, Altered expression of hepatic cytochromes P450 in mice deficient in one or more mdr1 genes, Mol. Pharmacol., 57, 188 Mayer, 1997, Full blockade of intestinal P-glycoprotein and extensive inhibition of blood–brain barrier P-glycoprotein by oral treatment of mice with PSC833, J. Clin. Invest., 100, 2430, 10.1172/JCI119784 Hendrikse, 1998, Complete in vivo reversal of P-glycoprotein pump function in the blood–brain barrier visualized with positron emission tomography, Br. J. Pharmacol., 124, 1413, 10.1038/sj.bjp.0701979 Polli, 1999, Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), and HIV protease inhibitor, Pharmaceut. Res., 16, 1206, 10.1023/A:1018941328702 Wacher, 1995, Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy, Mol. Carcinogen., 13, 129, 10.1002/mc.2940130302 van Asperen, 1997, Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833, Br. J. Cancer, 76, 1181, 10.1038/bjc.1997.530 Meerum Terwogt, 1998, Increased systemic exposure to oral paclitaxel in cancer patients treated with cyclosporin A, Lancet, 352, 285 Malingré, 2000, A phase I and pharmacokinetic study of oral paclitaxel, J. Clin. Oncol., 18, 2468, 10.1200/JCO.2000.18.12.2468 Cole, 1992, Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line, Science, 258, 1650, 10.1126/science.1360704 Cole, 1994, Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells, Cancer Res., 54, 5902 Cole, 1994, Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells, Cancer Res., 54, 5902 Hooijberg, 1999, Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2, Cancer Res., 59, 2532 Zaman, 1994, The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump, Proc. Natl. Acad. Sci. USA, 91, 8822, 10.1073/pnas.91.19.8822 Kruh, 1994, Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene, Cancer Res., 54, 1649 Breuninger, 1995, Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution, Cancer Res., 55, 5342 Leier, 1994, The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates, J. Biol. Chem., 269, 27807, 10.1016/S0021-9258(18)46856-1 Müller, 1994, Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport, Proc. Natl. Acad. Sci. USA, 91, 13033, 10.1073/pnas.91.26.13033 Evers, 1996, Basolateral localization and export activity of the human multidrug resistance-associated protein (MRP) in polarized pig kidney cells, J. Clin. Invest., 97, 1211, 10.1172/JCI118535 Loe, 1996, ATP-dependent 17β-estradiol 17-(β-d-glucuronide) transport by multidrug resistance protein (MRP), J. Biol. Chem., 271, 9683, 10.1074/jbc.271.16.9683 Schneider, 1995, Buthionine sulfoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation, Br. J. Cancer, 71, 738, 10.1038/bjc.1995.144 Zaman, 1995, Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein, Proc. Natl. Acad. Sci. USA, 92, 7690, 10.1073/pnas.92.17.7690 Rappa, 1997, Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins, Cancer Res., 57, 5232 Loe, 1998, Characterization of vincristine transport by the Mr 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione, Cancer Res., 58, 5130 Wijnholds, 1997, Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking MRP, Nature Med., 3, 1275, 10.1038/nm1197-1275 Lorico, 1997, Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione, Cancer Res., 57, 5238 Robbiani, 2000, The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobolization of dendritic cells to lymph nodes, Cell, 103, 757, 10.1016/S0092-8674(00)00179-3 Wijnholds, 1998, Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage, J. Exp. Med., 188, 797, 10.1084/jem.188.5.797 Wijnholds, 2000, Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood–cerebrospinal fluid barrier, J. Clin. Invest., 105, 279, 10.1172/JCI8267 Johnson, 2001, The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice, Cancer Res., 61, 1469 Lorico, 1996, Double knockout of the MRP gene leads to increased drug sensitivity in vitro, Cancer Res., 56, 5351 Allen, 2000, Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance, Cancer Res., 60, 5761 Zhang, 2001, Identification of a nonconserved amino acid residue in multidrug resistance protein 1 important for determining substrate specificity: evidence for functional interaction between transmembrane helices 14 and 17, J. Biol. Chem., 276, 34966, 10.1074/jbc.M105063200 Loe, 1996, Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles, J. Biol. Chem., 271, 9675, 10.1074/jbc.271.16.9675 Keppler, 1998, ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2, Chem. Biol. Interact., 111–112, 153, 10.1016/S0009-2797(97)00158-0 Holló, 1996, Transport properties of the multidrug resistance protein (MRP) in human tumour cells, FEBS Lett., 383, 99, 10.1016/0014-5793(96)00237-2 Evers, 2000, Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export, Br. J. Cancer, 83, 375, 10.1054/bjoc.2000.1262 Oude Elferink, 1995, Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport, Biochim. Biophys. Acta, 1241, 215, 10.1016/0304-4157(95)00006-D Mayer, 1995, Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes, J. Cell. Biol., 131, 137, 10.1083/jcb.131.1.137 Paulusma, 1996, Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene, Science, 271, 1126, 10.1126/science.271.5252.1126 Keppler, 2000, Hepatic secretion of conjugated drugs and endogenous substances, Semin. Liver Disease, 20, 265, 10.1055/s-2000-9391 Koike, 1997, A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells, Cancer Res., 57, 5475 Evers, 1998, Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA, J. Clin. Invest., 101, 1310, 10.1172/JCI119886 Cui, 1999, Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells, Mol. Pharmacol., 55, 929 Dietrich, 2001, Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats, Mol. Pharmacol., 59, 974, 10.1124/mol.59.5.974 Kala, 2000, The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic, J. Biol. Chem., 275, 33404, 10.1074/jbc.M007030200 Soignet, 1998, Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide, New Engl. J. Med., 339, 1341, 10.1056/NEJM199811053391901 Dai, 1999, Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system, Blood, 93, 268, 10.1182/blood.V93.1.268 Dietrich, 2001, Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, Carcinogenesis, 22, 805, 10.1093/carcin/22.5.805 Mottino, 2000, Expression and localization of multidrug resistant protein mrp2 in rat small intestine, J. Pharm. Exp. Ther., 293, 717 van Aubel, 2000, Expression and immunolocalization of multidrug resistance protein 2 in rabbit small intestine, Eur. J. Pharmacol., 400, 195, 10.1016/S0014-2999(00)00391-5 Schaub, 1997, Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules, J. Am. Soc. Nephrol., 8, 1213, 10.1681/ASN.V881213 Schaub, 1999, Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma, J. Am. Soc. Nephrol., 10, 1159, 10.1681/ASN.V1061159 Taipalensuu, 2001, Correlation of gene expression of ten drug efflux proteins of the human ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers, J. Pharmacol. Exp. Ther., 299, 164 Masuda, 1997, Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats, Cancer Res., 57, 3506 Miller, 2000, Xenobiotic transport across isolated brain microvessels studied by confocal microscopy, Mol. Pharmacol., 58, 1357, 10.1124/mol.58.6.1357 St.-Pierre, 2000, Expression of members of the multidrug resistance protein family in human term placenta, Am. J. Physiol., 279, R1495 Büchler, 1996, cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats, J. Biol. Chem., 271, 15091, 10.1074/jbc.271.25.15091 van Aubel, 1998, Adenosine triphosphate-dependent transport of anionic conjugates by the rabbit multidrug resistance-associated protein Mrp2 expressed in insect cells, Mol. Pharmacol., 53, 1062 Bakos, 2000, Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions, Mol. Pharmacol., 57, 760, 10.1124/mol.57.4.760 Chen, 1999, Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter, Mol. Pharmacol., 56, 1219, 10.1124/mol.56.6.1219 Cantz, 2000, MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells, Am. J. Physiol., 278, G522 Shapiro, 1997, Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities, Eur. J. Biochem., 250, 130, 10.1111/j.1432-1033.1997.00130.x Kondratov, 2001, Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein, Proc. Natl. Acad. Sci. USA, 98, 14078, 10.1073/pnas.241314798 Ito, 2001, Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity, J. Biol. Chem., 276, 38108, 10.1074/jbc.M105160200 Leslie, 2001, Transport of the β-O-glucuronide of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1), J. Biol. Chem., 276, 27846, 10.1074/jbc.M102453200 Shapiro, 1999, Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site, Eur. J. Biochem., 259, 841, 10.1046/j.1432-1327.1999.00098.x Kiuchi, 1998, cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3), FEBS Lett., 433, 149, 10.1016/S0014-5793(98)00899-0 Kool, 1999, MRP3, an organic anion transporter able to transport anti-cancer drugs, Proc. Natl. Acad. Sci. USA, 96, 6914, 10.1073/pnas.96.12.6914 König, 1999, Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane, Hepatology, 29, 1156, 10.1002/hep.510290404 Hirohashi, 1999, Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3), J. Biol. Chem., 274, 15181, 10.1074/jbc.274.21.15181 Hirohashi, 2000, ATP-dependent transport of bile salts by multidrug resistance-associated protein 3 (Mrp3), J. Biol. Chem., 275, 2905, 10.1074/jbc.275.4.2905 Zeng, 1999, Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents, Cancer Res., 59, 5964 Zeng, 2000, Transport of amphipathic anions by human multidrug resistance protein 3, Cancer Res., 60, 4779 Zelcer, 2001, Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3), J. Biol. Chem., 276, 46400, 10.1074/jbc.M107041200 Kool, 1997, Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologs of the multidrug resistance-associated resistance protein (MRP1), in human cancer cell lines, Cancer Res., 57, 3537 Scheffer, 2002, Tissue distribution and induction of human MRP3, Lab. Investigation, 82, 193, 10.1038/labinvest.3780411 Rost, 2001, Expression and localization of the multidrug resistance proteins mrp2 and mrp3 in human gallbladder epithelia, Gastroenterology, 121, 1203, 10.1053/gast.2001.28648 Hirohashi, 1998, Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats, Mol. Pharmacol., 53, 1068 Lee, 1998, Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter, Cancer Res., 58, 2741 Schuetz, 1999, MRP4: a previously unidentified factor in resistance to nucleotide-based antiviral drugs, Nat. Med., 5, 1048, 10.1038/12487 Lee, 2000, Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells, J. Natl. Cancer Inst., 92, 1934, 10.1093/jnci/92.23.1934 Chen, 2001, Transport of cyclic nucleotides and estradiol 17-β-d-glucuronide by multidrug resistance protein 4, J. Biol. Chem., 276, 33747, 10.1074/jbc.M104833200 van Aubel, 2002, The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubule: the putative efflux pump for urinary cAMP and cGMP, J. Am. Soc. Nephrol., 13, 595, 10.1681/ASN.V133595 McAleer, 1999, pABC11 (also known as MOAT-C and MRP5) a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells, J. Biol. Chem., 274, 23541, 10.1074/jbc.274.33.23541 Wijnholds, 2000, Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs, Proc. Natl. Acad. Sci. USA, 97, 7476, 10.1073/pnas.120159197 Jedlitschky, 2000, The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides, J. Biol. Chem., 275, 30069, 10.1074/jbc.M005463200 Doyle, 1998, A multidrug resistance transporter from human MCF-7 breast cancer cells, Proc. Natl. Acad. Sci. USA, 95, 15665, 10.1073/pnas.95.26.15665 Chen, 1990, Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein, J. Biol. Chem., 265, 10073, 10.1016/S0021-9258(19)38781-2 Lee, 1997, Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression, J. Cell. Biochem., 65, 513, 10.1002/(SICI)1097-4644(19970615)65:4<513::AID-JCB7>3.0.CO;2-R Miyake, 1999, Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes, Cancer Res., 59, 8 Allikmets, 1998, A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance, Cancer Res., 58, 5337 Berge, 2000, Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters, Science, 290, 1771, 10.1126/science.290.5497.1771 Lee, 2001, Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption, Nature Genet., 27, 79, 10.1038/83799 Allen, 1999, The mouse Bcrp/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin, Cancer Res., 59, 4237 Knutsen, 2000, Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines, Genes Cromosom. Cancer, 27, 110, 10.1002/(SICI)1098-2264(200001)27:1<110::AID-GCC14>3.0.CO;2-4 Ewart, 1998, ABC transporters involved in transport of eye pigment precursors in Drosophila melanogaster, Vol. 292, 213 Scheffer, 2000, Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines, Cancer Res., 60, 2589 Rocchi, 2000, The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane, Biochem. Biophys. Res. Comm., 271, 42, 10.1006/bbrc.2000.2590 Jonker, 2000, Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan, J. Natl. Cancer Inst., 92, 1651, 10.1093/jnci/92.20.1651 Litman, 2000, The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2), J. Cell Sci., 113, 2011, 10.1242/jcs.113.11.2011 Ross, 1999, Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines, J. Natl. Cancer Inst., 91, 429, 10.1093/jnci/91.5.429 Maliepaard, 1999, Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line, Cancer Res., 59, 4559 Kawabata, 2001, Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells, Biochem. Biophys. Res. Comm., 280, 1216, 10.1006/bbrc.2001.4267 Robey, 2001, Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells, Clin. Cancer Res., 7, 145 Komatani, 2001, Identification of breast cancer resistance protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure, Cancer Res., 61, 2827 Hazlehurst, 1999, Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line, Cancer Res., 59, 1021 Rabindran, 2000, Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein, Cancer Res., 60, 47 Robey, 2001, A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2), Biochim. Biophys. Acta, 1512, 171, 10.1016/S0005-2736(01)00308-X Brangi, 1999, Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells, Cancer Res., 59, 5938 Rabindran, 1998, Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C, Cancer Res., 58, 5850 Slapak, 1994, Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells, Blood, 84, 3113, 10.1182/blood.V84.9.3113.3113 Choi, 1988, An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene, Cell, 53, 519, 10.1016/0092-8674(88)90568-5 Volk, 2000, Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux, Cancer Res., 60, 3514 He, 1999, Fumitremorgin C analogs that reverse mitoxantrone resistance in human colon carcinoma cells, Med. Chem. Res., 9, 424 van Loevezijn, 2001, Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines, Biorgan. Med. Chem. Lett., 11, 29, 10.1016/S0960-894X(00)00588-6 Erlichman, 2001, The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux, Cancer Res., 61, 739 Zhou, 2001, The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype, Nature Med., 7, 1028, 10.1038/nm0901-1028 Scharenberg, 2002, The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature hematopoietic progenitors, Blood, 99, 507, 10.1182/blood.V99.2.507 Kruijtzer, 2002, Increased oral bioavailability of topotecan in combination with the Breast Cancer Resistance Protein and P-glycoprotein inhibitor GF120918, J. Clin. Oncol., 20, 2943, 10.1200/JCO.2002.12.116